Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen
Proteine und Peptide

Human Lipoprotein, a (Lpa), Active Protein

Produktgrößen
50 ug
£716,00
RPU56312-50UG
100 ug
£1115,00
RPU56312-100UG
1 mg
£4102,00
RPU56312-1MG
Über dieses Produkt
SKU:
RPU56312
Zusätzliche Namen:
AK38|APOA|LP|Lp(a)|Sinking Pre-B Beta-Lipoprotein
Anwendung:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Weitere Details:
Human Lipoprotein, a (Lpa), Active Protein is a purified Prokaryotic Protein.
Formulierung:
Freeze-dried powder
Immunogen:
Lipoprotein, a (Lpa)
Molekulargewicht:
39kda
Physischer Zustand:
freeze-dried
Reinheit:
>95%
Versandbedingungen:
Blue Ice
Lagerbedingungen:
-20[o]C Avoid freeze/thaw cycles.
Hersteller:
Biomatik
Typ:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
Figure . SDS-PAGE
Figure . Western Blot
Lipoprotein, a (Lpa) is a lipoprotein subclass. Lpa is assembled at the hepatocyte cell membrane surface, while other scenarios exist with regard to the location of assembly. It mainly exists in plasma. Lpa contributes to the process of atherogenesis. It also may enhance coagulation by inhibiting the function of tissue factor pathway inhibitor. Lpa carries cholesterol and binds atherogenic proinflammatory oxidized phospholipids as a preferential carrier of oxidized phospholipids in human plasma, which attract inflammatory cells to vessel walls and leads to smooth muscle cell proliferation. Moreover, Lpa also is hypothesized to be involved in wound healing and tissue repair, interacting with components of the vascular wall and extra cellular matrix. Besides, Fibronectin (FN) has been identified as an interactor of Lpa, thus a binding ELISA assay was conducted to detect the interaction of recombinant human Lpa and recombinant human FN. Briefly, Lpa were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to FN-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-Lpa pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of Lpa and FN was shown in Figure 1, and this effect was in a dose dependent manner.Figure. The binding activity of Lpa with FN.